RQ Biotechnology Ltd.

Mike Westby CEO of RQ Bio Financing led by Frazier Life Sciences with participation from new investors EQT Life Sciences, Forbion, Monograph , Wellington Management and founding investor LifeArc Ventures Proceeds support clinical development of lead programme RQB01 designed to provide seasonal influenza protection with a single administration Christian S. Schade appointed Executive Chairman LONDON, United Kingdom, June 24, 2026 — RQ Bio, a private biotechnology company developing long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations, today announced the completion of an oversubscribed $115 million (£85.5 million) Series A financing. The financing was led by Frazier Life Sciences, with participation from new investors EQT Life Sciences, Forbion, Monograph and Wellington Management alongside founding investor LifeArc Ventures, as well as shareholders Oxford Science Enterprises and the University of Oxford. The Company's lead programme, RQB01, currently in IND-enabling studies, is designed to deliver potent and broad protection against influenza through a differentiated dual mechanism of action targeting conserved epitopes resilient to seasonal variation. A combination of broad strain coverage, potent neutralizing activity and extended duration of action could establish a new pillar for influenza prophylaxis in vulnerable patient populations. "Influenza remains a serious and persistent threat for patients whose immune systems cannot rely on vaccination alone," said Mike Westby, Chief Executive Officer of RQ Bio. "Our vision is to develop a preventative therapy capable of delivering reliable protection for an entire flu season with a single administration. This financing will support clinical development of RQB01 as well as advance our proprietary antibody discovery approach towards a pipeline of assets for prophylaxis of respiratory viral diseases.” "RQ Bio has a strong team with extensive experience in infectious disease and what we believe is a highly innovative approach to influenza prevention," said Joe Cabral, Partner at Frazier Life Sciences , who joined the RQ Bio Board of Directors as part of the Series A financing. "We believe RQB01 possesses several differentiated attributes that will translate to efficacious, season-long prevention of flu in an attractive product format. We are excited to partner with the Company as it works towards advancing RQB01 into the clinic and through multiple important milestones.” “RQ was co-founded by an exceptional group of UK scientists and LifeArc Ventures several years ago. The RQ team have worked rapidly to progress their research in influenza prevention and with the funding announced today will be able to progress their lead programme into clinical development next year” added Clare Terlouw, Managing Partner at LifeArc Ventures . “The oversubscribed Series A is a testament to the scientific excellence and focused drive of the RQ team and is a great example of first class British science being backed for success on the global stage”. The Company also announced the appointment of biotechnology industry veteran Christian S. Schade as Executive Chairman. Christian most recently served as President and Chief Executive Officer of Halda Therapeutics, which was acquired by Johnson & Johnson for $3.05 billion in December 2025. He brings significant leadership and transaction experience from his numerous CEO and Board roles combined with nearly 20 years in corporate finance and capital markets at leading global investment banks. As Executive Chairman, Christian will work closely with the management team and Board of Directors to guide corporate strategy and support the Company's continued growth. About RQ Bio RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza with the goal of providing immediate, powerful, and long-lasting protection against severe viral disease in immunocompromised and high-risk subjects. The Company is advancing its lead product RQB01, a long-acting, potent and broadly protective antibody product, through IND-enabling studies. Founded in 2021, RQ Bio has a highly experienced team with proven success in developing long-acting antibodies against viral targets. RQ Bio is backed by a strong syndicate of investors – Frazier Life Sciences, EQT Life Sciences, Forbion, Monograph, Wellington Management, and LifeArc Ventures as well as Oxford Science Enterprises and the University of Oxford. Media Contacts Frazer Hall, Sandi Greenwood MEDiSTRAVA rqbio@medistrava.com Mike Westby, CEO RQ Bio media@rqbiotechnology.com Attachment Mike Westby

June 24, 2026 EQT Life Sciences joins new investors Frazier Life Sciences, Forbion, Monograph and Wellington Management, alongside existing investors LifeArc, Oxford Science Enterprises and Oxford University Innovation, in RQ Bio's oversubscribed USD 115 million Series A financing RQ Bio is developing antibody therapies to prevent seasonal influenza in high-risk and immunocompromised populations, with the Series A supporting its clinical progression and broader infectious disease pipeline As part of the financing, RQ Bio appointed Christian S. Schade as Executive Chairman, having most recently served as President and CEO of Halda Therapeutics EQT Life Sciences is pleased to announce participation in a USD 115 million (GBP 86 million) Series A financing in RQ Bio, a UK biotechnology company developing antibody therapies for the prevention of influenza in high-risk and immunocompromised populations through one of its managed funds. The financing was led by Frazier Life Sciences, with participation from new investors EQT Life Sciences, Forbion, Monograph and Wellington Management, alongside existing investors LifeArc, Oxford Science Enterprises and Oxford University Innovation. The Series A funding will support the clinical development of RQ Bio's lead program, RQB01, and help advance the company's broader pipeline of therapies for other infectious diseases. Founded in 2021 by four leading infectious disease scientists, RQ Bio is developing new antibody therapies that aim to protect people from seasonal flu for an entire season with just one treatment. The company's lead programme is progressing towards clinical development and is intended to provide broad protection for high-risk patients, including those who remain vulnerable despite existing vaccination strategies. EQT Life Sciences will support RQ Bio as it advances RQB01, its lead programme towards the clinic and continues to expand its broader pipeline. Drawing on its experience backing innovative biotechnology companies through clinical development, EQT Life Sciences will work alongside management and the investor syndicate to help scale the organisation, strengthen development capabilities and support the company's long-term growth. Felice Verduyn - van Weegen, Partner at EQT Life Sciences, said: "Influenza continues to pose a significant burden for high-risk populations, despite the availability of existing treatments. RQ Bio's single-administration approach to durable, season-long protection addresses a clear unmet need among the patients who remain most vulnerable. We are excited to support this European company as it advances towards the clinic and expands its pipeline." Mike Westby, CEO of RQ Bio, said: "Influenza remains a serious and persistent threat for patients whose immune systems cannot rely on vaccination alone. Our vision is to develop a preventative therapy capable of delivering reliable protection for an entire flu season with a single administration. This financing will support clinical development of RQB01 as well as advance our proprietary antibody discovery approach towards a pipeline of assets for prophylaxis of respiratory viral diseases." As part of the financing, RQ Bio appointed Christian S. Schade as Executive Chairman, who most recently served as President and CEO of Halda Therapeutics that was acquired by Johnson & Johnson for USD 3.0 billion in December 2025. He brings extensive leadership, board and transaction experience from across the biotechnology sector. As Executive Chairman, he will work closely with the management team and Board of Directors to guide corporate strategy and support the Company's continued growth. The content above comes from the network. if any infringement, please contact us to modify.

Biotechnology startup RQ Bio has snagged a nine-figure funding round to support development of a drug it believes to be capable of providing broad, long-lasting protection against seasonal influenza.The London-based biotech said Wednesday it raised 85.5 million pounds, or $115 million, to advance a program known as RQB01. Currently in preclinical testing, the therapy has an undisclosed differentiated dual mechanism targeting parts of the virus that remain unchanged even after mutations. RQ Bio claims this approach could help ward off flu-related illness from a variety of different strains, with a single dose providing protective effects that persist for a full season.The financing round was led by Frazier Life Sciences, included participation from founding investor LifeArc Ventures, and involved other well-known firms such as Forbion and EQT Life Sciences.“We believe RQB01 possesses several differentiated attributes that will translate to efficacious, season-long prevention of flu in an attractive product format, said Joe Cabral, Partner at Frazier Life Sciences, in a statement.Despite the availability of preventive shots, influenza remains a persisent health problem. The effectiveness of those shots can vary year to year, and some people arent able to receive them due to allergies to some vaccine components. On-demand treatments are only modestly helpful, too.Some biotechs are working on newer solutions. Moderna is developing a flu vaccine based on the kind of messenger RNA technology that can be quickly harnessed to keep up with circulating viral strains. U.S. regulators could approve that shot by early August. Merck, meanwhile, acquired Cidara Therapeutics last year to get ahold of a preventive antiviral therapy thats shown early promise and is now in late-stage testing.RQ Bio didnt reveal many details about RQB01 in its statement, but claimed that the drug has a chance to establish a new pillar for influenza prophylaxis in vulnerable patient populations, such as those at high risk of severe illness or people with weakened immune systems. The company is developing other preventive therapies for different respiratory viral infections, too.Alongside the fundraise, the company named Christian Schade as its executive chairman. Schade was recently president and CEO of Halda Therapeutics, a cancer drug developer Johnson & Johnson acquired late last year for over $3 billion. '